We are live on ! Find out more
GILD icon

Gilead Sciences

1,504 hedge funds and large institutions have $81.5B invested in Gilead Sciences in 2017 Q3 according to their latest regulatory filings, with 123 funds opening new positions, 601 increasing their positions, 613 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $69.4B → $81.5B (+$12.2B)

8% more funds holding in top 10

Funds holding in top 10: 8996 (+7)

2.03% more ownership

Funds ownership: 74.96%76.99% (+2%)

1% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 124

2% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 613

1% less funds holding

Funds holding: 1,5201,504 (-16)

28% less call options, than puts

Call options by funds: $1.87B | Put options by funds: $2.61B

Holders
1,504
Holders Change
-16
Holders Change %
-1.05%
% of All Funds
37.49%
Holding in Top 10
96
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+7.87%
% of All Funds
2.39%
New
123
Increased
601
Reduced
613
Closed
124
Calls
$1.87B
Puts
$2.61B
Net Calls
-$732M
Net Calls Change
-$83M
Name Holding Trade Value Shares
Change
Change in
Stake
VFA
601
Virtus Fund Advisers
Connecticut
$4.04M +$3.81M +49,882 New
3C
602
361 Capital
Colorado
$4.03M +$3.81M +49,772 New
Cerity Partners
603
Cerity Partners
New York
$4.02M +$638K +8,347 +20%
Citadel Advisors
604
Citadel Advisors
Florida
$3.99M -$171M -2,232,320 -98%
ECM
605
Evergreen Capital Management
Washington
$3.98M +$480K +6,280 +15%
MA
606
Montag & Associates
Georgia
$3.98M +$3.75M +49,083 New
MCA
607
Morris Capital Advisors
Pennsylvania
$3.97M -$64.8K -848 -2%
VIA
608
Vident Investment Advisory
Georgia
$3.97M +$933K +12,202 +33%
RAM
609
Roanoke Asset Management
New Jersey
$3.96M -$242K -3,164 -6%
CCA
610
Catalyst Capital Advisors
New York
$3.94M -$616K -8,055 -14%
SG Americas Securities
611
SG Americas Securities
New York
$3.94M -$29.4M -383,932 -89%
SSCM
612
Summit Street Capital Management
New York
$3.93M
RMCM
613
Reynders McVeigh Capital Management
Massachusetts
$3.91M -$312K -4,083 -8%
SFPIA
614
Stevens First Principles Investment Advisors
California
$3.89M -$121K -1,585 -3%
CEI
615
Clark Estates Inc
New York
$3.89M +$252K +3,300 +7%
TF
616
TIAA FSB
Florida
$3.88M -$132K -1,728 -3%
CYG
617
Clean Yield Group
Vermont
$3.87M -$311K -4,071 -8%
DY
618
Dowling & Yahnke
California
$3.82M +$164K +2,151 +5%
B
619
BancorpSouth
Mississippi
$3.78M +$185K +2,415 +5%
MML Investors Services
620
MML Investors Services
Massachusetts
$3.75M -$809K -10,583 -19%
SWP
621
Stratos Wealth Partners
Ohio
$3.74M -$2.39M -31,280 -40%
OMCS
622
Old Mutual Customised Solutions
South Africa
$3.73M +$161K +2,100 +5%
BCM
623
Bluefin Capital Management
New York
$3.72M +$3M +39,203 +581%
NEI
624
Northwest & Ethical Investments
Ontario, Canada
$3.71M -$1.88M -24,574 -35%
HAIM
625
Hunter Associates Investment Management
Pennsylvania
$3.71M -$148K -1,940 -4%

GILD Hedge Fund Activity: Q3 2017 in Review

1,504 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2017, worth a combined $81.5B — up 18% from $69.4B a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of GILD and 123 opened new positions — a net loss of 1 holder — while 613 trimmed existing stakes and 601 added.

The largest buyer was Dodge & Cox, adding an estimated $758M. The largest seller was Susquehanna International Group, cutting an estimated $359M.

  • 1,504 institutional investors held Gilead Sciences (GILD) as of Q3 2017, down from 1,520 in Q2 2017.
  • Funds reported $81.5B of Gilead Sciences stock for Q3 2017, up 18% quarter-over-quarter.
  • 123 funds opened new Gilead Sciences positions in Q3 2017 and 124 closed out, a net change of -1 holder.
  • The largest Gilead Sciences buyer in Q3 2017 was Dodge & Cox, an estimated $758M added.
  • The largest Gilead Sciences seller in Q3 2017 was Susquehanna International Group, an estimated $359M sold.

Based on aggregated 13F filings for Q3 2017.